• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a method of reducing skin inflammation and / or treating inflammatory skin disease, pain or pruritus by topical application of a composition comprising totarol or a pharmaceutically acceptable ester thereof.
    公开号:KR20040035798A
    申请号:KR10-2004-7003884
    申请日:2002-09-17
    公开日:2004-04-29
    发明作者:젠디메니코제라드제이.
    申请人:존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드；
    IPC主号:
    专利说明:

    Method for treating skin disorders
    [1] Field of invention
    [2] The present invention relates to a method of treating skin diseases.
    [3] Background of the Invention
    [4] Totarol belongs to the terpenoid family of natural foods. The main source of totarol is the Podocarp tree (Podocarpus totara), native to New Zealand. Totarol can be extracted from the heartwood of the rotten grape karp tree.
    [5] Totarol S. S. mutans, b. B. subtilis, S. A. aureus and blood. It is an antimicrobial agent that has a strong effect on gram positive organisms, including Acnes. Topical use of totarol as an antimicrobial agent is described in Japanese Patent Publication No. 2,700,071 B2.
    [6] The antioxidant effects of totarol have also been described using in vitro systems. This includes inhibition of lipid peroxidation and inhibition of linoleic acid oxidation in mitochondria and microsomes (Haraguchi, H. et al., Planta Medica 63: 213-215 (1997)).
    [7] Applicants have surprisingly found that totarol is also effective as a topical anti-inflammatory agent.
    [8] Summary of the Invention
    [9] In one aspect, the invention features a method of reducing skin inflammation by topical application of a composition comprising totarol or a pharmaceutically acceptable ester thereof.
    [10] In another aspect, the invention features a method of treating an inflammatory skin disease by topically applying a composition comprising totarol or a pharmaceutically acceptable ester thereof.
    [11] In another aspect, the inflammatory skin disease is an inflammatory skin disease other than acne.
    [12] In another aspect, the invention features a method of treating pain or pruritus by topical application of a composition comprising totarol or a pharmaceutically acceptable ester thereof.
    [13] Other features and advantages of the invention will be apparent from the description and the claims.
    [14] Detailed description of the invention
    [15] Those skilled in the art are contemplated to utilize the present invention to its fullest extent based on the description herein. The following specific embodiments are to be construed as merely illustrative and are not intended to limit the remainder of the specification in any way.
    [16] Unless stated otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In addition, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference. Unless stated otherwise, all percentages of ingredients are in weight percent (weight / weight percent).
    [17] Justice
    [18] As used herein, "topical application" or "topical application" means painting or applying directly to the skin using a topical instrument or hand, such as, for example, a wipe.
    [19] As used herein, “pharmaceutically acceptable” means totarol or ester, pharmaceutically active ingredient or inactive ingredient thereof, which is inadequate toxicity, incompatibility, instability, hypersensitivity in proportion to the appropriate benefit / risk ratio. It is suitable for use in contact with tissues (eg skin) in the absence of allergic reactions.
    [20] As used herein, a “safe and effective amount” is a compound or composition (eg, totarol or pharmaceutical) that is sufficient to cause a significant change under conditions that are controlled or treated, but low enough to avoid serious side effects. Acceptable esters thereof). Safe and effective amounts of the compound or composition may include the age and physical condition of the end user, the severity of the disease to be treated / prevented, the duration of treatment, the nature of the concurrent therapy, the specific compound or composition used, the particular pharmaceutically acceptable topical used It depends on factors such as a carrier.
    [21] Totarol
    [22] The composition used in the present invention comprises totarol or a pharmaceutically acceptable ester thereof. Totarol is a compound having the structure of Formula 1.
    [23]
    [24] In one embodiment, the composition comprises a safe and effective amount of totarol or a pharmaceutically acceptable ester thereof. In one embodiment, the composition comprises a safe and effective amount of totarol. In one embodiment, the totarol is isolated from natural sources. Examples of such natural sources include, but are not limited to, grapecap trees and plants from the Cupressacaea family. In one embodiment, totarol is prepared synthetically. In one embodiment, the totarol or pharmaceutically acceptable ester thereof is present in the composition in an amount of about 0.01 to about 20% by weight of the total composition, especially about 0.1 to about 5% by weight of the total composition.
    [25] Pharmaceutically Acceptable Salts or Esters
    [26] Examples of pharmaceutically acceptable salts include polymers, as well as pharmaceutically acceptable organic acids, such as acetic acid, lactic acid, maleic acid, citric acid, malic acid, ascorbic acid, succinic acid, benzoic acid, methesulfonic acid, toluenesulfonic acid or pamoic acid. Salts with acidic acids such as tannic acid or carboxymethyl cellulose, and salts with inorganic acids such as hydrohalic acid such as hydrochloric acid, sulfuric acid or phosphoric acid. Examples of pharmaceutically acceptable esters include, but are not limited to, C2-C6 alkyl esters such as methyl esters and ethyl esters.
    [27] Topical composition
    [28] Topical compositions useful in the present invention include formulations suitable for topical application to the skin. In one embodiment, the composition comprises totarol or a pharmaceutically acceptable ester thereof and a pharmaceutically acceptable topical carrier. In one embodiment, the pharmaceutically acceptable topical carrier is about 50 to about 99.99 weight percent of the composition (eg, about 80 to about 95 weight percent of the composition).
    [29] The composition is a lotion, cream, gel, stick, spray, shaving cream, ointment, cleansing liquid wash and solid bar, shampoo, paste, powder, mousse, wipe, patch, nail lacquer, wound dressing, adhesive band, hydrogel, film And makeup (eg, concealer, foundation, mascara, and lipstick), but can be made into a variety of product types, including but not limited to. These product types may include several pharmaceutically acceptable topical carriers, including but not limited to solutions, emulsions (eg microemulsions and nanoemulsions), gels, solids, micelles and liposomes. The following are non-limiting examples of such topical carriers. Other topical carriers may be formulated by one of ordinary skill in the art.
    [30] Topical compositions useful in the present invention may be formulated as a solution. The solution typically comprises an aqueous solvent (eg, about 50 to about 99.99% by weight, for example about 90 to about 99% by weight) of a pharmaceutically acceptable aqueous solvent.
    [31] Topical compositions useful in the present invention may be formulated as a solution comprising an emollient. Such compositions preferably comprise about 2 to about 50% softener. As used herein, "emollient" means a substance used for skin protection as well as to prevent or alleviate drying. Various suitable softeners are known and can be used herein. See International Cosmetic Ingredient Dictionary and Handbook, eds., Wenninger and McEwen, pp. 1656-61, 1626, and 1654-55 (The Cosmetic, Toiletry, and Frangrance Assoc., Washington, DC, 7 th Edition, 1997) (hereinafter referred to as the "ICI Handbook") are examples of a number of suitable materials. It includes.
    [32] Lotions can be prepared from these solutions. Lotions typically include about 1% to about 20% (eg about 5% to about 10%) emollients and about 50% to about 90% (eg about 60% to about 80%) water.
    [33] Another type of product that can be formulated from solution is a cream. Creams typically comprise about 5% to about 50% (eg about 10% to about 20%) softener and about 45% to about 85% (eg about 50% to about 75%) of water.
    [34] Another type of product that can be formulated from solution is an ointment. Ointments may include simple bases of animal or vegetable oils, or semisolid hydrocarbons. The ointment may comprise about 2 to about 10% softener and about 0.1 to about 2% thickener. A more complete description of thickeners or viscosity increasing agents useful herein can be found in the ICI Handbook pp. 1693-1697.
    [35] Topical compositions useful herein can also be formulated as emulsions. If the carrier is an emulsion, about 1 to about 10% (eg about 2 to about 5%) of the carrier includes an emulsifier. Emulsifiers may be nonionic, anionic or cationic. Such emulsifiers are described in ICI Handbook pp. 1673-1686.
    [36] Lotions and creams may be formulated as emulsions. Typically, such lotions contain 0.5 to about 5% of an emulsifier. Such creams typically contain about 1% to about 20% (eg about 5% to about 10%) softener, about 20% to about 80% (eg 30% to about 70%) water and about 1% to about 10% (eg about emulsifier) 2 to about 5%).
    [37] Oil-in-water and water-in-oil single emulsion skin care preparations such as lotions and creams are well known in cosmetic products and are useful in the present invention. Multiphase emulsion compositions such as water-in-oil type are also useful in the present invention. Generally, such single or multiphase emulsions include water, emollients and emulsifiers as essential components.
    [38] Topical compositions of the invention may also be formulated as a gel (eg, an aqueous gel with a suitable gelling agent). Suitable gelling agents for aqueous gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives such as hydroxymethyl cellulose and hydroxypropyl cellulose. Suitable gelling agents for oils such as mineral oils include, but are not limited to, hydrogenated butylene / ethylene / styrene copolymers and hydrogenated ethylene / propylene / styrene copolymers. Such gels typically contain about 0.1 to 5% by weight of the gelling agent.
    [39] The topical compositions of the present invention may also be formulated in solid formulations such as wax-based sticks, soap bar compositions, powders or wipe containing powders.
    [40] Liposomal formulations are also useful compositions of this invention. Examples of liposomes are monolayer, multilayer and hydrophobic liposomes, with or without phospholipids. Liposomes typically have a size of about 50 nm to about 10 μm, for example about 0.1 to about 1 μm. Such compositions can be prepared by first combining hesperetin with phospholipids such as dipalmitoylphosphatidyl choline, cholesterol and water. Examples of such epidermal lipids include, but are not limited to, glyceryl monoesters and diesters, polyethylene fatty ethers and sterols. Liposomal formulations can be incorporated into one of the above carriers (eg, suspended in solution, gel or oil-in-water emulsion) to prepare liposome formulations.
    [41] Micellar formulations are also useful compositions of this invention. Such compositions can be prepared using single chain surfactants and lipids. Micelles typically have a size of about 1 to about 100 nm, such as about 10 to about 50 nm. The micelle formulation can be incorporated into one of the above carriers (eg gel or solution) to prepare the micelle formulation.
    [42] Topical compositions useful in the present invention, in addition to the components mentioned above, may include various additional oil-soluble and / or water-soluble materials commonly used in compositions for use on the skin, hair and nails at levels set in the art.
    [43] Additional Pharmaceutical Active Agents
    [44] In one embodiment, the topical composition further comprises another pharmaceutically active agent in addition to totarol or a pharmaceutically acceptable ester thereof. "Pharmaceutical active agent" means a compound having a cosmetic or therapeutic effect on skin, hair or nails, such as lightening agents, darkening agents, such as self-tanning agents, anti-acne agents, sun conditioners, antibacterial agents, anti-inflammatory agents, Antifungals, antiparasitic agents, external analgesics, sunscreens, light protectors, antioxidants, keratinizers, detergents / surfactants, moisturizers, nutrients, vitamins, energy enhancers, sweat inhibitors, astringents, bleaches, hair removers, solidifying agents, anticaking agents, And hair, nail and / or skin conditioning agents.
    [45] In one embodiment, the formulation is hydroxy acid, benzoyl peroxide, sulfur resorcinol, ascorbic acid, D-panthenol, hydroquinone, octyl methoxycinnimate, titanium dioxide, octyl salicylate, homosalate, avo Benzone, polyphenolic acid, carotenoids, free radical scavengers, spin traps, retinoids such as retinic acid, retinol and retinyl palmitate, keramids, polyunsaturated fatty acids, essential fatty acids, enzymes such as fortease ( Examples: trypsin), enzyme inhibitors, minerals, hormones (e.g. estrogens), steroids (e.g. hydrocortisone), 2-dimethylaminoethanol, copper salts (e.g. copper chloride), coenzyme Q10, peptides (e.g. international publications) Peptides described in WO 00/15188), lipoic acid, amino acids (e.g., proline and tyrosine), vitamins, lactobionic acid, acetyl-coenzyme A, niacin, riboflavin, thiamine, ribose, electron transporter ( Examples include, but are not limited to, groups consisting of NADH and FADH2), other vegetable extracts such as aloe vera and soy, and derivatives and mixtures thereof. Pharmaceutically active agents are usually present in the compositions of the present invention in an amount from about 0.001% to about 20% by weight of the composition, for example from about 0.01% to about 10% by weight, for example from about 0.1% to about 5% by weight.
    [46] Examples of vitamins include, but are not limited to, vitamin A, vitamin B (eg, vitamin B3, vitamin B5 and vitamin B12), vitamin C, vitamin K, vitamin E and derivatives thereof.
    [47] Examples of hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, salicylic acid, citric acid and tartaric acid.
    [48] In one embodiment, the composition further comprises another anti-inflammatory agent. In one embodiment, the composition is a corticosteroid such as hydrocortisone, betamethasone, nomethasone, alclomethasone, clobetasol, prednicarbate and pharmaceutically acceptable salts and esters thereof, nonsteroidal Anti-inflammatory agents such as COX inhibitors, LOX inhibitors and p38 kinase inhibitors, immunosuppressive agents such as cyclosporin and cytokine synthesis inhibitors.
    [49] In one embodiment, the composition further comprises an analgesic and / or antipruritic agent. In one embodiment, the composition comprises menthol, camphor, antihistamines, local anesthetics such as tetracaine, lidocaine, prilocaine, benzocaine, bupivacaine, mepivacaine, dibucaine, ethidocaine, buta Caine, cyclomethicine, hexylcaine, propparacaine, lopivacaine, capsaicin and oatmeal.
    [50] The anti-inflammatory, analgesic or antipruritic agent is usually present in the composition in an amount of about 0.001 to about 10% by weight, especially about 0.01 to about 2% by weight.
    [51] In one embodiment, the composition comprises an antioxidant. Examples of antioxidants include water soluble antioxidants such as sulfhydryl compounds and derivatives thereof (such as sodium metabisulfite and N-acetyl-cysteine), lipoic acid, dihydrolipoic acid, resveratrol, lactoferrin, ascorbic acid and ascorbic acid Derivatives such as ascorbyl palmitate and ascorbyl polypeptides, but are not limited thereto. Oil-soluble antioxidants suitable for use in the compositions of the present invention include, but are not limited to, butylated hydroxytoluene, retinoids such as retinol and retinyl palmitate, tocopherols such as tocopheryl acetate, tocotrienol and ubiquinone It doesn't work. Natural extracts containing antioxidants suitable for use in the compositions of the present invention include extracts containing flavonoids, isoflavonoids and derivatives thereof (e.g. genistein and diadzein), extracts containing resveratrol and the like. However, this is not limiting. Examples of such natural extracts include grape seed, green tea, pine bark and blobs.
    [52] Other substances
    [53] Various other materials may also be present in compositions useful in the present invention. It includes wetting agents, preservatives, chelating agents and pH adjusting agents. Examples of such agents are described in ICI Handbook, pp. 1661-62, 1654-55, 1626 and 1653. In addition, topical compositions useful herein may include conventional cosmetic auxiliaries such as dyes, colorants, and flavorings.
    [54] mineral water
    [55] The composition of the present invention can be prepared using mineral water. In one embodiment, the mineral water has a mineral deposition degree (ie, the sum of the concentrations of the anions and cations present in the water) of about 200 mg / L or more (eg, about 300 to about 1,000 mg / L). In one embodiment, the mineral water comprises at least about 10 mg / L calcium and / or at least about 5 mg / L magnesium.
    [56] Topical application
    [57] In one embodiment, the composition is applied topically at least once a week, for example once or twice a day. In one embodiment, the composition is applied topically until inflammation, inflammatory skin disease, pain and / or pruritus are reduced or eliminated until the user is satisfied.
    [58] Examples of inflammatory skin diseases include acne, eczema, pruritus, infections, dermatitis, e.g. contact dermatitis, atopy dermatitis, seborrheic and allergic dermatitis, multiple light rashes, folliculitis, alopecia, toxic ivy, insect bites, acne Inflammation and stimuli caused by exogenous factors such as chemicals, trauma, contaminants (eg tobacco smoke) and sun exposure are included, but are not limited thereto.
    [59] Example 1:
    [60] Allergic contact dermatitis is an animal model of skin inflammation that simulates various aspects of human skin inflammation [Young JM, De Young LM, Cutaneous Models of Inflammation for the Evaluation of Topical and Systemic Pharmacological Agents; In: Pharmacological Methods in the Control of Inflammation, Alan R. Liss, Inc, pp. 215-231 (1989). This model is used to demonstrate the anti-inflammatory activity of totalol. Inflammatory responses are established by using oxazolone as a chemical sensitizer. Topical anti-inflammatory formulations are assessed by applying a dose of oxozolone to the ear, followed by application of the test formulation and measuring its ability to inhibit ear swelling response.
    [61] In this assay, totalol (Mende-DEK Limited, Masterton, New Zealand) evaluates hydrocortisone, a steroid known to inhibit allergic contact dermatitis. Albino male CD-1 mice, 7-9 weeks old, are induced in the abdomen shaved with 50 μl of 3% oxazolone in acetone / corn oil (day 0). On day 5, 20 μl of 2% oxazolone in acetone is applied to the dorsal left ear of the mouse. The test formulation is applied to the left ear 1 hour after oxazolone administration in 70% ethanol / 30% propylene glycol excipient (20 μl). The right mouse does not manage. Mice are sacrificed by inhalation of CO 2 24 hours after oxazolone administration, the left and right ears are removed, then a 7-mm biopsy is taken from each ear and weighed. The difference in biopsy weight between the right and rat ears is calculated and listed in Table 1. The anti-inflammatory effect of the compound is evident as an inhibition of the increase in ear weight.
    [62] cureCapacity (weight / volume%)% Inhibition of ear swelling reaction *Hydrocortisone0.184.2 0.0165.5 0.00136.0 TotarolOne82.3 0.380.0 0.0344.6
    [63] * % Inhibition = ((excipient biopsy weight-treated biopsy weight) / excipient biopsy weight) x 100
    [64] Totarol is very effective as a topical anti-inflammatory agent under dose dependent inhibition of inflammatory response. At both of these high doses, totalol is equally active against the high doses of hydrocortisone.
    [65] Example 2:
    [66] Sensory nerve inflammation, also called nerve inflammation, is a form of inflammation caused by sensory nerve activation in the skin. Certain natural substances that act on vanilloid receptors cause nerves (C-fibers) to release inflammatory neuropeptides as substance P and decytonin gene related peptides. In mouse skin, edema reactions occur rapidly upon application of vanilloid receptor activator, capsaicin or resinous toxin. Compounds that inhibit the response to sensory nerve stimulation are useful as topical analgesics, itch inhibitors, or emollients for irritated or damaged skin (US Pat. No. 6,090,811).
    [67] Albino male CD-1 mice 7 to 9 weeks old are used. Resin-releasing toxin alone (0.05%) or a mixture of the test compound and 0.05% resin-releasing toxin is prepared in acetok. 20 μl volume of solution is applied to the left ear (10 mice per treatment group). The right ear does not process. Mice are sacrificed by inhalation of CO 2 30 minutes after application of the solution. The left and right ears are removed and a 7-mm biopsy is removed from each ear and then weighed. Calculate the difference in biopsy weight between the right and rat ears. % Inhibition is calculated by comparing treatments with resin secretory toxin alone. The anti-edema effect of the compound is evident as an inhibition of the increase in ear weight. The results are shown in Table 2.
    [68] cureTopical dose (% weight / volume)% Inhibition of ear edema *Arbanil0.526.8 TotarolOne46.6
    [69] * % Inhibition = ((excipient biopsy weight-treated biopsy weight) / excipient biopsy weight) x 100
    [70] Totarol is very effective in this model. As a result, the known analgesic compounds arbanyl and capsaicin homologs (described in US Pat. No. 4,898,887) are also active.
    [71] While the present invention is described in conjunction with the detailed description thereof, it is understood that the above description is intended to explain the scope of the present invention and not limit it, and is limited by the appended claims. Other aspects, advantages, and modifications are within the scope of the claims.
    权利要求:
    Claims (22)
    [1" claim-type="Currently amended] A method of reducing skin inflammation comprising topical application of a composition comprising totarol or a pharmaceutically acceptable ester thereof.
    [2" claim-type="Currently amended] A method of treating an inflammatory skin disease other than acne comprising topically applying a composition comprising totarol or a pharmaceutically acceptable ester thereof.
    [3" claim-type="Currently amended] The method of claim 2, wherein the disease is eczema.
    [4" claim-type="Currently amended] The method of claim 2, wherein the disease is psoriasis.
    [5" claim-type="Currently amended] The method of claim 2, wherein the disease is dermatitis.
    [6" claim-type="Currently amended] A method of treating pain or pruritus, comprising topically applying a composition comprising totarol or a pharmaceutically acceptable ester thereof.
    [7" claim-type="Currently amended] The method of claim 6, wherein the pain is treated.
    [8" claim-type="Currently amended] The method of claim 6, wherein the pruritus is treated.
    [9" claim-type="Currently amended] The method of claim 1 wherein the composition comprises totarol.
    [10" claim-type="Currently amended] The method of claim 2, wherein the composition comprises totarol.
    [11" claim-type="Currently amended] The method of claim 3, wherein the composition comprises totarol.
    [12" claim-type="Currently amended] The method of claim 4, wherein the composition comprises totarol.
    [13" claim-type="Currently amended] The method of claim 5, wherein the composition comprises totarol.
    [14" claim-type="Currently amended] 8. The method of claim 7, wherein the composition comprises totarol.
    [15" claim-type="Currently amended] The method of claim 8, wherein the composition comprises totarol.
    [16" claim-type="Currently amended] The method of claim 1, wherein the composition further comprises salicylic acid or corticosteroids.
    [17" claim-type="Currently amended] The method of claim 2, wherein the composition further comprises a corticosteroid.
    [18" claim-type="Currently amended] The method of claim 3, wherein the composition further comprises a corticosteroid.
    [19" claim-type="Currently amended] The method of claim 4, wherein the composition further comprises a corticosteroid.
    [20" claim-type="Currently amended] The method of claim 5, wherein the composition further comprises a corticosteroid.
    [21" claim-type="Currently amended] 8. The composition of claim 7, wherein the composition is tetracaine, lidocaine, prilocaine, benzocaine, bupivacaine, mepivacaine, dibucaine, ethidocaine, butacacaine, cyclomethicaine, hexylcaine, propparacaine or ropi. A method further comprising baccaine.
    [22" claim-type="Currently amended] The method of claim 8, wherein the composition further comprises menthol or camphor.
    类似技术:
    公开号 | 公开日 | 专利标题
    US9492412B2|2016-11-15|Penetrating pharmaceutical foam
    US8703105B2|2014-04-22|Oleaginous pharmaceutical and cosmetic foam
    US9345737B2|2016-05-24|Topical treatment of keratotic lesions using hamelia patens
    ES2198476T3|2004-02-01|No-sintasa inhibitors.
    ES2320054T3|2009-05-18|Pharmaceutical compositions that include an amphoteric surfactant, a polypropoxyled cetilic alcohol and polar pharmaco.
    US8394759B2|2013-03-12|Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes
    JP3921202B2|2007-05-30|Anti-irritant rosacea treatment
    ES2322269T3|2009-06-18|Spray compositions containing a pharmaceutical active principle, at least a volatile silicone and a non-volatile oleous phase.
    CA2165521C|2002-07-16|Topical composition containing a p substance antagonist
    KR100604402B1|2006-07-25|Topical compositions for regulating the oily/shiny appearance of skin
    JP4046363B2|2008-02-13|Active vitamin D3 emulsion lotion
    JP3162028B2|2001-04-25|Uses of phloroglucinol in cosmetics
    EP0907351B2|2012-04-18|Cosmetic or cosmetic preparation for smoothing and tightening the skin in the case of subcutaneous fatty tissue problems, particularly cellulite
    ES2248042T5|2011-06-03|Topical composition that includes n-acetylglucosamine.
    US4247547A|1981-01-27|Tretinoin in a gel vehicle for acne treatment
    US5990100A|1999-11-23|Composition and method for treatment of psoriasis
    TWI274588B|2007-03-01|Novel topical formulations
    US7368122B1|2008-05-06|Skin cream
    US6667045B2|2003-12-23|Topical applications for skin treatment
    US6955816B2|2005-10-18|Anti-aging skin care composition and uses thereof
    KR100775803B1|2007-11-12|Dermal compositions containing coenzyme q as the active ingredient
    DE60018881T2|2006-02-16|Extracts from mother herb | against inflammatory diseases
    US5425954A|1995-06-20|Topical amino acid - vitamin complex compositions for pharmaceutical and cosmetic use
    US10322155B2|2019-06-18|Topical formulation and uses thereof
    KR20140060475A|2014-05-20|Compositions containing anti-acne agents and the use thereof
    同族专利:
    公开号 | 公开日
    US20030104016A1|2003-06-05|
    BR0212576A|2004-10-13|
    JP2005507882A|2005-03-24|
    CA2460326A1|2003-03-27|
    ES2319271T3|2009-05-06|
    WO2003024436A2|2003-03-27|
    US6881756B2|2005-04-19|
    DE60231050D1|2009-03-19|
    AT421877T|2009-02-15|
    WO2003024436A3|2003-10-30|
    EP1435927A2|2004-07-14|
    EP1435927B1|2009-01-28|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2001-09-17|Priority to US32266201P
    2001-09-17|Priority to US60/322,662
    2002-09-17|Application filed by 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드
    2002-09-17|Priority to PCT/US2002/029368
    2004-04-29|Publication of KR20040035798A
    优先权:
    申请号 | 申请日 | 专利标题
    US32266201P| true| 2001-09-17|2001-09-17|
    US60/322,662|2001-09-17|
    PCT/US2002/029368|WO2003024436A2|2001-09-17|2002-09-17|Method for treating skin disorders|
    [返回顶部]